Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Palvella Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA), MAIA Biotechnology, Inc. (MAIA) and...

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), MAIA Biotechnology, Inc. (MAIA) and Palvella Therapeutics (PVLA)

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Palvella Therapeutics, with a price target of $222.00. Slut...

Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spectral AI (MDAI) and Palvella Therapeutics (PVLA) ...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PVLA	$122.82	+2.32%	168.17K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PVLA	$122.82	+2.3%	168.17K
3
4
5
6

PVLA

PVLA

Dividend Overview

Get Palvella Therapeutics Inc. Data in Excel

Get Palvella Therapeutics Inc. Data in Excel